High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.
about
First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studiesAllogeneic stem cell transplantation with matched sibling donor versus autologous stem cell transplantation for newly diagnosed Multiple MyelomaFirst-line double high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myelomaThe effects of allogeneic stem cell transplantation with matched sibling donor versus autologous stem cell transplantation for newly diagnosed multiple myelomaFirst line vs delayed transplantation in myeloma: Certainties and controversiesAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeTreatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersCancer stem cells: relevance to clinical transplantationDiagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvementAdvances in the autologous and allogeneic transplantation strategies for multiple myelomaSalvage second hematopoietic cell transplantation in myelomaAutologous Hematopoietic Stem Cell Transplantation-10 Years of Data From a Developing CountryRisk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myelomaBortezomib in the management of multiple myeloma.Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple MyelomaCancer stem cells-clinical relevance.Patient, Physician and Contextual Factors Are Influential in the Treatment Decision Making of Older Adults Newly Diagnosed with Symptomatic Myeloma.Complete response after autologous stem cell transplant in multiple myelomaMultiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapyClinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms MacroglobulinemiaInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Concise review: Emerging concepts in clinical targeting of cancer stem cellsReduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myelomaStem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.Determining the optimal time for bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplant in the treatment of multiple myelomaChallenges in multiple myeloma diagnosis and treatment.Targeted treatments to improve stem cell outcome: old and new drugs.The evolving background for high-dose treatment for myeloma.Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis.The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.Clinical impact of chromosomal aberrations in multiple myeloma.Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.Autologous stem cell transplantation and multiple myeloma cancer stem cells.Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program.Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.Immunotherapeutic approaches to treat multiple myeloma
P2860
Q24197999-B1B70D3B-4A91-4FCC-A21F-01ACC81BF021Q24198198-20A2B6FE-EE39-41EF-9303-B9EC914B7596Q24243542-6A0D130D-148A-4A4E-85CD-038EDE2CF2FCQ26471825-77D417C5-79E7-44C2-A8BB-C4C8E0557B6FQ26745957-A7D3C5EB-4F4A-4D7A-8FAC-E159FE74A279Q26782868-7BA2CC45-2230-41FB-80DD-9A2B26033D79Q26851202-663BB20B-22FD-4579-AB6E-9D76A1A95152Q27008959-14B5E285-7733-49E4-9257-185A6D5C920DQ27011865-05E7663B-4A1A-4C58-96A8-D3D3964FED3BQ27014801-1D11E08F-A25B-4FFD-93E3-E6C490201172Q30416452-EA94F624-984E-4DC6-8260-D11F9E610ECCQ30962747-CC65F0FE-3AD5-4D92-8544-A3E61C4869ECQ33434435-651D3110-8836-40B2-BC28-398E2084EA54Q33648344-5C1AFE79-71FE-4D9B-B1F8-3FFF96FC0AA5Q34418462-03DD981E-B744-4C7D-B333-790BB4DACE6EQ34694749-01691CDC-8534-4FCA-BF5A-89ED7E263966Q34729707-74480894-D1E4-4EC1-B815-3B50559319CEQ34781514-38266F28-113D-4193-BBF7-4939F92ECB26Q35000475-BAA66BA6-B872-4D7E-8648-DD371D4BBC9DQ35061518-4F7D4DC0-2669-4219-A89A-A738D101F2FFQ35097338-D239D130-0120-4202-B218-E3642D8851DFQ35802414-4EAD1302-3969-4DAD-BEDA-3C6ADCCABDE6Q35971159-A747EB9E-0FB8-4FDB-B46E-87EC0D798741Q36148528-F9F7A9F0-6A61-48E6-969B-90D5BCFC1AFCQ36765107-F9642E25-AEE5-4CD1-8198-62DBF82F0E61Q36767656-2C078F31-096D-4709-886A-13A855CE38B1Q36852225-2D582271-983D-4ECA-98AD-A7CE8E4355B9Q36927960-85A86D59-9293-4BDE-87E8-6B31A903CFFAQ36956271-12203C11-8C5B-427A-8948-AF906444E8D9Q37162610-B8EFB772-2743-40A2-8427-4A7E489659F2Q37367737-1546D06C-8098-4854-8B3E-CDF8F89BC315Q37530452-ED4610FA-6812-48A2-AA21-389629773C42Q37698645-2CFEC76F-40C6-47E4-8779-CBDA9DE4D3EBQ37800884-2B9F6082-DB08-4854-BE3A-A824A2ABD0B2Q37821077-5F56451B-B502-4BAF-B668-A66B6BAE7775Q37827173-15743332-CA7F-4A50-B310-724325FB5A3CQ37973864-87BA1F09-CF8F-495F-B29E-D92DD1E5AA31Q38025703-A6F96EEB-CC47-4F84-B747-40B5E9EE73C8Q38095526-9FBDB10D-50C3-43DF-B9BF-10A4F8D77DABQ38171067-32C8CE12-B465-404E-94AA-820658286B6A
P2860
High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
High-dose therapy with single ...... randomized controlled trials.
@ast
High-dose therapy with single ...... randomized controlled trials.
@en
type
label
High-dose therapy with single ...... randomized controlled trials.
@ast
High-dose therapy with single ...... randomized controlled trials.
@en
prefLabel
High-dose therapy with single ...... randomized controlled trials.
@ast
High-dose therapy with single ...... randomized controlled trials.
@en
P2093
P1476
High-dose therapy with single ...... randomized controlled trials.
@en
P2093
Corey S Cutler
Edwin P Alyea
John Koreth
Kenneth C Anderson
Nikhil C Munshi
Rajesh Behl
Robert J Soiffer
Robert L Schlossman
P304
P356
10.1016/J.BBMT.2006.09.010
P577
2007-02-01T00:00:00Z